 Stealth BioTherapeutics Corp NASDAQ: MITO has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy GA secondary to dry age-related macular degeneration. Although the trial did not meet its primary endpoints, a key secondary. 